Quinoxaline-based UCHL5 inhibitor as a next-generation proteasome-targeting anticancer agent beyond 20S inhibition
DK-7, a quinoxaline-based UCHL5 inhibitor, selectively triggers ER stress and apoptosis, effectively overcomes bortezomib resistance, and exhibits antitumor activity in solid tumors. These findings highlight UCHL5 as a promising therapeutic target and suggest quinoxaline-based DUB inhibitors as a next-generation proteasome-targeted strategy with broad clinical potential.
Authors
- Seong-Ah Shin (ORCID: https://orcid.org/0000-0002-6738-1448)
- Misun Won (ORCID: https://orcid.org/0000-0001-6626-0647)
- Hyun Seung Ban (ORCID: https://orcid.org/0000-0002-2698-6037)
- Jeong Hee Moon (ORCID: https://orcid.org/0000-0002-0119-7218)
- Sreenivasulu Godesi
- Ga Seul Lee (ORCID: https://orcid.org/0000-0002-4984-2925)
- Changseong Kim
- Joohan Lee
- Kyeong Lee
- Areum Seo
- Hossam Nada
- Tae-Su Han
- Joo-Young Im
- Young-Dae Gong
- Tae-Hee Han
- Inseo Hwang
- Minjae Kim
Institutions
- Chungbuk National University (KR)
- Genome Research Foundation (KR)
- Dongguk University (KR)
- Korea Research Institute of Bioscience and Biotechnology (KR)
Publication Details
- Journal
- Journal of Advanced Research
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.jare.2026.02.012
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00